## 1 Identification of targets for drug repurposing to treat COVID-19 using a Deep

2 Learning Neural Network

## 3 Author names

- 4 Si-Han Wang<sup>a#</sup>, Yu-Hsuan Tang<sup>a#</sup>, Hao Hsu<sup>a#</sup>, Chu-Nien Yu<sup>a</sup>, Oscar Kuang-Sheng
- 5 Lee<sup>a,b,c,d</sup>

### 6 Affiliations

- a) Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei,
  Taiwan.
- 9 b) Stem Cell Research Center, National Yang Ming Chiao Tung University, Taipei,
- 10 Taiwan.
- 11 c) Department of Medical Research, Taipei Veterans General Hospital, Taipei,
  12 Taiwan.
- 13 d) Department of Orthopedics, China Medical University Hospital, Taichung,
  14 Taiwan.
- 15 #The equal contributions footnote specifies contributed to the manuscript equally.

## 16 Contact information of the corresponding author:

- 17 Oscar Kuang-Sheng Lee, MD, PhD
- 18 ORCID: 0000-0001-5232-5374
- 19 Tel: +886-2-28757391
- 20 Fax: +886-2-28757435
- 21 E-mail address: oscarlee9203@gmail.com
- 22

### 23 Abstract

24 The COVID-19 pandemic has resulted in a global public health crisis requiring 25 immediate acute therapeutic solutions. To address this challenge, we developed a useful 26 tool deep learning model using the graph-embedding convolution network (GECN) 27 algorithm. Our approach identified COVID-19-related genes and potential druggable 28 targets, including tyrosine kinase ABL1/2, pro-inflammatory cytokine CSF2, and pro-29 fibrotic cytokines IL-4 and IL-13. These target genes are implicated in critical processes 30 related to COVID-19 pathogenesis, including endosomal membrane fusion, cytokine 31 storm, and tissue fibrosis. Our analysis revealed that ABL kinase inhibitors, lenzilumab 32 (anti-CSF2), and dupilumab (anti-IL4R $\alpha$ ) represent promising therapeutic solutions 33 that can effectively block virus-host membrane fusion or attenuate hyperinflammation 34 in COVID-19 patients. Compared to the traditional drug screening process, our GECN algorithm enables rapid analysis of disease-related human protein interaction networks 35 36 and prediction of candidate drug targets from a large-scale knowledge graph in a cost-37 effective and efficient manner. Overall, Overall, our results suggest that the model has 38 the potential to facilitate drug repurposing and aid in the fight against COVID-19. 39

40

41 Word count of the article is 3604.

### 42 **1. Introduction**

43 Coronavirus disease 2019 (COVID-19) emerged in December 2019 and has rapidly spread worldwide, resulting in a global public health crisis. Severe acute 44 respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is a 45 single-stranded positive RNA virus with spikes on its envelope [1]. As of 5 April 2023, 46 47 the World Health Organization COVID-19 Dashboard has reported 762,201,169 48 confirmed cases and 6,889,743 deaths worldwide. Many patients develop pneumonia 49 within weeks of showing symptoms and increased inflammatory cytokines which can 50 lead to respiratory failure and death [2]. The traditional drug discovery method, with a 51 long discovery period (10–15 years) and low success rate (2.01%) [3], has failed to 52 meet the urgent need for a COVID-19 cure.

Numerous monoclonal antibodies are currently being developed as systemic 53 54 therapies for COVID-19; however, their large size, instability, and low density of 55 binding sites (two per 150 KDa antibody) make them unsuitable for intranasal delivery 56 [4]. To overcome this challenge, deep learning, a subset of artificial intelligence (AI) 57 algorithms, can accelerate drug development and repurposing to slow down the 58 progression of acute disease. Deep learning uses multiple interconnected layers to 59 recognize complex patterns in data, which is useful for finding correlations between 60 inputs and outputs for complex problems. Unlike the traditional protein structure 61 prediction problem, locally connected graph neural networks can accurately model the 62 structure-to-sequence mapping problem [5]. The Graph Convolutional Network (GCN) 63 is an approach to graph embedding that transforms graph information into spectral domains for convolutional calculation. This is done using the Laplacian matrix, 64 65 Chebyshev polynomials, or other methods [6-10]. GCNs are powerful in processing 66 network data, and their representative tasks include node classification, link prediction, 67 and graph generation., as they can combine features with a hidden layer to aggregate 68 important information from different nodes. By combining features with a hidden layer, 69 GCNs can effectively aggregate important information from different nodes. This 70 ability to recognize complex patterns in data and find correlations between inputs and 71 outputs for complex problems makes GCNs an excellent choice for prediction models. 72 Additionally, GCNs' locally connected graph neural networks can accurately model the 73 structure-to-sequence mapping problem, providing greater accuracy compared to 74 traditional protein structure prediction methods. Moreover, recent studies have shown

75 that deep learning, including GCNs, outperforms classic machine learning methods in 76 assisting drug repurposing, allowing the screening of existing drugs as potential 77 treatments for SARS-CoV-2. The development of affordable approaches for the 78 effective treatment of COVID-19 is challenging without foreknowledge of the complex 79 networks connecting drugs, targets, SARS-CoV-2, and diseases. Current studies suggest that using the in-silico method to identified some potential antiviral drugs such 80 81 as remdesivir [11, 12], mefuparib [13], and toremifene [14, 15], while drugs like baricitinib [16], melatonin [17], and dexamethasone [18, 19] have been identified as 82 83 potential host-targeted therapies to attenuate cytokine storms in COVID-19 patients. 84 The results of clinical trials for these drugs are controversial [20]. However, most of 85 these studies focused on SARS-CoV-2 proteins with known functions, such as the spike protein and 3C-like (3CL) protease, or a host protein with a known interaction with 86 87 viruses, such as ACE2 and TMPRSS2. The approach of focusing only on SARS-CoV-88 2 proteins and host proteins with known interactions with viruses significantly limits 89 the potential targets for drug development because the role and functional annotations 90 of many other host proteins are mostly ignored. In this study, we propose a new AI-91 assisted drug development method, the graph-embedding convolution network (GECN), 92 that utilizes the functional annotations of host proteins to identify potential druggable 93 targets for SARS-CoV-2 pathogenic mechanisms. By investigating tissue specificity, 94 physiological functions, and cell signaling pathways, our approach aims to expedite 95 drug discovery new insights into the druggable targets and pathogenic mechanisms of 96 COVID-19.

#### 98 2. Materials and Methods

## 99 **2.1 Data preprocessing**

100 The protein interaction data were extracted from the STRING dataset (v 11.0) [21] with 101 Homo sapiens axotomy (ID 9606), and edges between pairs of all associated genes 102 were constructed, regardless of whether it was physically binding or not. The edges were not weighted, and no edge attributes were added. GO terms, such as cell 103 104 components, biological processes, and molecular functions, were extracted and 105 clustered using the semantic similarity method [22, 23]. In our study, semantic 106 similarity was represented by the minimum number of steps across the graph required 107 to connect two terms, weighted by how specific or general the terms are, and was 108 calculated with the following formula (2):

109 
$$Sim(go_i, go_j) = \frac{2 \max_{go \in S(go_i, go_j)} \{IC(go)\}}{IC(go_i) + IC(go_j)}$$
(2)

where  $go_i$  and  $go_j$  are a pair of GO terms and  $Sim(go_i, go_j)$  are their semantic similarities.  $S(go_i, go_j)$  is the subset of GO terms shared between  $go_i$  and  $go_j$  after propagating up the GO DAG using the "is\_a" and "part\_of" relations.  $IC(go_i)$  is the information content (IC) of a GO term, which is defined as the frequency of  $go_i$ , relative to the total number of GO terms in the UniProt Gene Ontology Annotation (GOA) database [24, 25], specifically calculated using the formula (3):

116 
$$IC(GO_i) = -\log\left(\frac{\{go:go_i \in GOA\}}{\{go:go \in GOA\}}\right) (3)$$

Pathway IDs from Reactome were clustered by propagating along the Reactome [26,
27] graph and were mapped to the top super pathway. Finally, the "probability of loss
of function intolerance" extracted from ExAC (v 1.0) [28] was normalized.

## 121 **2.2 Graph convolution network (GCN)**

122 The GCN algorithm included a feature matrix and an adjacency matrix [9]. A feature 123 matrix was  $N \times F^0$  dimension, with N being the number of nodes and  $F^0$  being the feature 124 numbers in each node. An adjacency matrix represented the structure of the graph, and 125 the dimension was N x N.

Each neural network layer can be written as a non-linear function (4)[29], as shown below, where H (0) = X and H(1) = Z (or z for graph-level outputs), and l is the number of layers.

129 
$$H^{(l+1)} = f(H^{(l)}, A)$$

130 Here, W(l) is a weight matrix for the l-th neural network layer. Additionally,  $\hat{A} = A + 131$  I, where I is the identity matrix,  $D^{\hat{}}$  is the diagonal node degree matrix of  $\hat{A}$ , and  $\sigma(\cdot)$  is

132 a non-linear activation function, like ReLU.

Besides, we use multilayer GCN to combine neighboring node features with self-loops
by summing and taking weighted average of their feature vectors which employ a
multilayer GCN with the following layer-wise propagation rule:

- 136
- 137

$$f\left(H^{(l)},A\right) = \sigma\left(\widehat{D}^{-1/2}\widehat{A}\widehat{D}^{-1/2}H^{(l)}W^{(l)}\right)$$

The Variational Graph Autoencoder (VGA) is a type of neural network used for generating molecular graphs and consists of an encoder and a decoder. The encoder of the VGA, which employs edge condition convolution, embeds the original graph into a continuous vector space. The decoder generates a probabilistic fully connected graph according to the predefined number of nodes and updates the parameters through approximate graph matching to improve the reconstruction ability of the autoencoder.

144 We constructed the VGA model using three layers of Graph Convolutional Network (GCN) encoder with hidden unit dimensions of 512, 256, and 256, respectively. We 145 146 used an inner product decoder to produce the output. The VGA is a type of Variational 147 Autoencoder (VAE) that projects input features into a multivariate latent distribution 148 and samples the values of latent features from this distribution. To make the sampling 149 process differentiable and enable reliable training of the model, the reparameterization 150 trick is used. The reparameterization trick involves sampling from a standard normal 151 distribution and then transforming the sampled values to produce the latent features. 152 The formula for the reparameterization trick is given as (1):

153

 $z = \mu + \varepsilon \times \sigma (1)$ 

where  $\varepsilon \sim N(0,1)$  and z is the latent feature. By using the reparameterization trick, the model can backpropagate gradients through the sampling process, allowing for end-toend training of the variational autoencoder.

157

158 A neighbor sampler with a batch size of 1,024 was applied, and the loss function 159 contained reconstruction loss and KL loss. Reconstruction loss is the cross-entropy loss 160 of positive edges (interactions) and negative edges (non-interactions), whereas KL loss 161 is the KL divergence between the output distribution of encoder N( $\mu$ , $\sigma$ ) and standard 162 normal distribution N(0,1). The AdamW optimizer was used [30], and 100 training

163 epochs were trained without early termination. Finally, the model with the best AUC164 value was saved.

To predict potential links and appropriate evaluation of the performance of our 165 166 model, fixed-threshold metrics and test set sampling were required. We sampled those 167 negative edges where the geodesic distances were equal to 2. The shortest paths 168 between these pairs of nodes were equal to two, and improvements in these pairs were 169 weighted more than at greater distances. To decrease the computational complexity of 170 spectral graph convolution, the Chebyshev polynomial was used to replace the eigen-171 decomposition of a Laplacian matrix [31]. The Chebyshev polynomial utilized the 172 recurrence relation to approach the value of eigen-decomposition and increase the 173 efficiency of model training. The hyperparameter k in the Chebyshev convolution 174 represents a receptive field that can lead the algorithm to see more local values. In our 175 model, we set k to 2. Cluster-GCN is a type of GCN algorithm that is suitable for 176 training by exploiting the graph clustering structure [32], In this study, a graph 177 clustering algorithm identified a block of nodes associated with a dense subgraph. It 178 then restricted the neighborhood search within this subgraph. This simple but effective 179 strategy led to significantly improved memory and computational efficiency while 180 achieving a test accuracy comparable to that of previous algorithms.

181

#### 182 2.3 K-fold cross-validation

183 K fold cross-validation was used to verify the performance of the model. It split the 184 data into five groups and randomly selected one of them as the test set. This approach 185 estimated the performance of the model using the new data.

186

## 187 2.4 Protein-protein docking using MOE software

188 In silico protein-protein docking of ABL1 against TNF and ABL2 against BTK was 189 performed using the MOE software [33]. PDB files of ABL1 (PDB ID: 1AWO), TNF 190 (PDB ID: 1TNF), ABL2 (PDB ID: 5NP3), and BTK (PDB ID: 5XYZ) were 191 downloaded from the RCSB PDB and imported into the MOE software. The pre-bound 192 ligands were first removed from the PDB structures. Protein structures were then 193 prepared using the MOE "Protein Preparation" tool (to correct atom lost issues) and 194 MOE "Protonate 3D" tool (to add hydrogen atoms and to assign ionization states throughout the system). Water molecules farther than 4.5 Å from proteins were deleted. 195 Active sites of TNF and BTK were found using the MOE "Site Finder" tool (Compute, 196

Site Finder), and ABL1 or ABL2 were docked to all these sites later. Prepared structures were docked by MOE "Dock" tool (Compute, Dock, Protein-protein). Docking structures with a minimum S score indicated that the highest binding affinity was selected for further interaction analyses. Interaction bond type, bond length, and bond energy were indicated by MOE "Protein Contacts" tool (Protein, Protein Contacts).

#### 203 **3. Results**

## **3.1 Experiment setting of the graph embedding convolution network algorithm**

205 The GECN algorithm consists of two deep learning methods: GE and GCN, as shown 206 in Fig. 1. The GE model uses a Variational Graph Autoencoder (VGA) to extract latent 207 features from raw data, which are then used as input node features for the second deep 208 learning model, DeepGCN, to perform GCN as a classifier. The VGA encoder maps 209 raw data into a latent distribution with means and standard deviations, and a 210 reparameterization trick is employed to make the VGA suitable for backpropagation. 211 This makes the process of stochastic sampling of latent features from the latent 212 distribution differentiable. The decoder of the VGA reconstructs the latent features into 213 the adjacency matrix. The unsupervisedly trained VGA utilizes the reconstruction error 214 and Kullback-Leibler divergence to encode latent features, which are then fed as node 215 feature inputs into the supervisedly trained DeepGCN for classification. In brief, 216 DeepGCN utilizes a combination of latent features as nodes, PPI network as graph 217 structure, and disease-related genes as labels for training. The model is then trained 218 with focal loss to minimize the difference between predicted and true labels and is 219 enhanced with residual and dense connections for improved performance in comparison 220 to traditional GCN with a deeper structure. It predicts potential protein targets that 221 interact with COVID-19.

222

223 In this study, we conducted experiments on a biological network dataset consisting of 224 a total of 533,138 data points. These data points were divided into a training set and a 225 test set. The training set contained 479,825 positive edges, representing interactions 226 between pairs of genes. The test set included 53,313 positive edges and an equal number 227 of negative edges, representing the absence of interactions between pairs of genes. To 228 select the negative edges, we chose unconnected node pairs that had a geodesic distance 229 of two. This sampling strategy was employed to mitigate the effects of class imbalance 230 and to allow for a more accurate assessment of the model's performance in link 231 prediction.

232

We employed a VGA to compress the data and retrieve the latent features. The VGA was evaluated on a complete version of the graph without removing any edges. To train the model, we used the Adam optimization algorithm with an initial learning rate set to a predefined value. The batch size was fixed at 1024, and we trained the model for a

total of 100 epochs. To mitigate the risk of overfitting, we applied L2 regularization

238 (weight decay) with a specified weight value. The learning rate adjustment function

used was the cosine annealing function, and the loss function employed was the cross-

240 entropy loss function. During training, we calculated the loss between the predicted

241 values and the ground truth. The model's parameters were then optimized by the Adam

242 optimization algorithm based on the calculated loss. To address the data imbalance

243 problem, we used a cost matrix to give more attention to false positives and omissions.



## 245 Fig. 1. Overview of the graph-embedding convolution network (GECN)

- algorithm. The GECN algorithm combines graph embedding and graph
- 247 convolution network. A variational graph autoencoder learned embedding
- 248 gene features and protein interaction networks to latent features. DeepGCN
- 249 predicts disease-associated genes based on latent features.
- 250

## **3.2 Performance of the graph embedding convolution network algorithm**

252 The performance of our deep learning model was evaluated using various metrics, 253 including the area under the receiver operating characteristic curve (AUC) and fixed-254 threshold metrics such as accuracy, recall, precision, F1 score, and F2 score. The test 255 set achieved an AUC of 0.92 (Fig. 2a), while the accuracy of the model with the threshold applied was 0.84, with a recall of 0.87 and a precision of 0.82 (Fig. 2b). The 256 257 F1 and F2 scores were 0.84 and 0.86, respectively. The confusion matrix of the test set revealed 10,488 new predicted links, suggesting potential interactions between pairs of 258 259 genes that were not constrained to physical binding due to the nature of the STRING 260 dataset and may include metabolic pathways or cellular processes.



262

Fig. 2. Evaluation of link prediction of the protein interaction network.
The receiver operating characteristic (ROC) curve (a) and confusion matrix
(b) of link prediction were evaluated from the test set.

#### 267 **3.3 Predicting and Assessing Protein-Protein Interactions between COVID-19**

## 268 and Associated Genes through Molecular Docking Analysis

269 To understand virus-host protein interactions have found that SARS-CoV-2 270 can interfere with various signaling pathways in host cells. The immune evasion of 271 SARS-CoV-2 improves viral survival and triggers pathogenic mechanisms in host 272 cells. Analyzing the host protein associated with the known COVID-19 related 273 genes can reveal new druggable targets and can help heal COVID-19 patients by 274 blocking pathogenic signaling pathways or potential virus-host protein interactions. 275 Our analysis identified several predicted interacting genes that showed potential 276 associations with COVID-19-related genes ABL1 (39.13%) and ABL2 (26.09%). 277 Less than 1% of genes interacted with other COVID-19-related genes (see 278 Supplementary Table 1). Notably, ABL1-TNF and ABL2-BTK had the highest 279 probabilities of predicted links for ABL1 and ABL2, respectively.

To estimate the likelihood of physical binding in the predicted association, we used the Molecular Operating Environment (MOE) software [34, 35]. We selected the links with the highest probabilities of prediction and the docking structures of ABL1-TNF and ABL2-BTK as candidates. Our analysis revealed that the best docking structure of ABL1-TNF achieved an S score of -67.63 and a root-mean-square deviation (RMSD) of 0.98, while ABL2-BTK achieved an S score of -51.39 and RMSD of 1.16, indicating a high probability of physical interaction between these two pairs.

287 The 2D interaction diagram (Fig. 3) shows the three phenomena. First, amino acid 288 residues are exposed in solution. Second, binding pockets are formed. Finally, the 289 important amino acid residues are involved in protein interactions. For example, the 290 side chain of Arg131 on TNF forms a hydrogen bond with the side chain of His95 on ABL1 (bond length = 3.345 Å, energy = 4.500 kcal/mol), the backbone of Gln88 on 291 292 TNF forms a hydrogen bond with the side chain of Asn94 on ABL1 (bond length =293 3.205 Å, energy = 3.100 kcal/mol), and the side chain of Glu23 on TNF forms an ionic 294 bond with the side chain of Lys87 on ABL1 (bond length = 4.006 Å, energy = 0.501295 kcal/mol). The backbone of Glu640 on BTK forms a hydrogen bond with the side chain of Lys87 on ABL2 (bond length = 3.439 Å, bond energy = 1.300 kcal/mol), and the 296 297 side chain of Gln496 on BTK forms a hydrogen bond with the side chain of Arg103 on ABL2 (bond length = 3.199 Å, bond energy = 0.700 kcal/mol). 298



299



300

Fig. 3. Docking structure with the lowest energy simulated by
 Molecular Operating Environment. The docking positions of the two
 proteins are clearly shown in Fig. 3 in the protein surface diagram (upper

304	left panel) and ribbon diagram (upper right panel). (a) Docking structures
305	of ABL1- tumor necrosis factor (TNF) and ABL1 (Protein Data Bank
306	(PDB) ID: 1AWO) are shown as blue ribbons, whereas those of TNF (PDB
307	ID: 1TNF) are shown as green ribbons; the skeletons are binding sites. (b)
308	Docking structures of ABL2- Bruton's tyrosine kinase (BTK) and ABL2
309	(PDB ID: 5NP3) are shown as pink ribbons and those of BTK (PDB ID:
310	5XYZ) are shown as green ribbons; the skeletons are binding sites.

311

# 312 3.4 Predicting Potential Target Genes in SARS-CoV-2 Affected Host Protein 313 Networks using GECN Algorithm

The GECN algorithm was tested using 15 COVID-19 associated genes from CTD in 2019 as a graph center to construct SARS-CoV-2 affected host protein networks. The algorithm embedded the latency features from the autoencoder, with an accuracy of  $0.99 \pm 0.01$  (mean  $\pm$  SD), precision of  $0.64 \pm 0.11$ , recall of  $0.77 \pm 0.15$ , and F1 of 0.69 $\pm 0.08$ . The top five predicted targets were Interleukin (IL)-4, Colony-stimulating factor 2 (CSF2), IL-13, CXCL8, and PRL; CXCL8 was confirmed as a COVID-19 associated gene in 2021.

321 In the second stage, COVID-19 associated genes from CTD in 2021 were used as 322 the graph center to construct a SARS-CoV-2 affected host protein network. The 323 algorithm embedded the latency features from the autoencoder, with an accuracy of 324  $0.99 \pm 0.01$  (mean  $\pm$  SD), precision of  $0.69 \pm 0.06$ , recall of  $0.80 \pm 0.10$ , and F1 of 0.74325  $\pm$  0.06. The top three predicted targets were CSF2, IL-4, and IL-13. These target genes 326 include ALB1/ALB2 (which might be involved in the entry of SARS-CoV-2 into host 327 cells), CSF2 (which might participate in the cytokine storm, inducing severe 328 syndrome), and IL-4 and IL-13 (which might participate in pulmonary fibrosis).

#### 330 **4. Discussion**

The efficacy and safety of the COVID-19 pandemic has resulted in significant 331 societal challenges. However, clinicians have no drug recommendations without a 332 proper understanding of the virus and its mechanisms. In this context, in silico 333 334 approaches led to the advancement of machine learning techniques and docking 335 methods in drug repurposing. In this study, we developed a deep learning algorithm, 336 the GECN, to predict COVID-19 related genes integrated with functional annotations 337 of human genes. However, focusing on specific targets such as spike protein, 3CL 338 protease, and MPro in SARS-CoV-2 or ACE2 and TMPRSS2 would restrict the 339 candidate screening scope. Most interactive proteins in humans are associated with 340 endomembrane compartments or vesicle trafficking pathways, indicating the essential 341 role of human proteins during infection. Therefore, this study identified 332 physical interactions which provide form COVID-19 Research Group of Quantitative 342 343 Biosciences Institute between human proteins and SARS-CoV-2 proteins, providing a 344 comprehensive view of the host-pathogen interactome.

345 Our GECN algorithm predicted ABL1, ABL2, CSF2, IL-4, and IL-13 as 346 candidates for COVID-19 treatment target genes, which were successfully identified as 347 having a binding affinity with COVID-19-related proteins. The use of deep learning 348 algorithms, such as the GECN used in this study, can be a powerful tool for analyzing 349 large amounts of data and identifying patterns that may not be apparent to humans. 350 Previous studies [36, 37] on the ABL family and coronavirus the ABL kinase inhibitor, 351 GNF2, GNF5 [36], imatinib [36, 37], imatinib mesylate [38], nilotinib [38], and 352 dasatinib [38] can reduce the viral titer of coronavirus by preventing syncytia formation. 353 These results also suggest that ABL1 and ABL2 are involved in the process of 354 coronavirus infection. Experiments on ABL kinase inhibitor treatment of SARS-CoV-355 2 have shown promising results that imatinib mesylate suppresses the replication of SARS-CoV-2 in Vero-E6 cell[39]. Moreover, study on nilotinib, dasatinib, and 356 357 imatinib reported antiviral activity only of nilotinib but not of dasatinib or imatinib in 358 Vero-E6 cells and Calu-3 cells [40]. Imatinib did not exhibit any antiviral activity in 359 Caco-2 cells, as documented in a previous study [41]. Three randomized clinical trials 360 are currently underway to study imatinib's efficacy in treating COVID-19. 361 NCT04357613 (France), NCT04394416 (USA), and EudraCT2020-001236-10 (The 362 Netherlands), are currently underway to study the therapeutic efficacy of imatinib in 363 COVID-19 patients, controversial results are derived from different ABL kinase 17

364 inhibitors, and more studies are needed to determine its therapeutic effect. Furthermore, the GECN-predicted targets, CSF2, IL-4, and IL-13, have been associated with 365 COVID-19 in previous clinical studies [42-44]. GM-CSF is involved in the 366 367 inflammatory phase, which induces a cytokine storm, and IL-4 and IL-13 are involved 368 in the tissue repair phase, which causes pulmonary fibrosis. Therefore, clinical trials 369 have focused on these three targets. Lenzilumab is a monoclonal antibody against GM-370 CSF with high binding affinity and low immunogenicity [45]. Lenzilumab neutralizes 371 the GM-CSF effect and blocks signal transduction to myeloid progenitor cells. 372 Lenzilumab has been shown to reduce the risk of death or respiratory failure in 373 hospitalized COVID-19 patients [45]. Dupilumab is an IL-4R $\alpha$  antagonist used in the 374 treatment of atopic dermatitis, which blocks IL-13 and IL-4 signaling, may have 375 potential as a treatment for COVID-19. A retrospective analysis of a trial of two-cohorts 376 of patients infected with SARS-CoV2- confirmed the benefit with a lower risk of death 377 in patients.

378 In addition, recent studies have developed innovative models for designing picomolar 379 miniprotein inhibitors [4]. These models leverage computer-generated scaffolds 380 designed to optimize target binding, folding, and stability around an ACE2 helix that 381 interacts with the spike receptor binding domain or are docked against the RBD to 382 identify new binding modes. These de novo design approaches offer a innovative and 383 promising solution to the COVID crisis. However, clinicians have the critical timing of 384 the pandemic outbreak, there is a dire need for potent therapeutics immediatly. 385 Although designing drugs specific to SARS-CoV-2 is the gold standard solution, it 386 requires complex and time-consuming procedures. Our GECN algorithm is built up 387 with a knowledge database to further extend drug repurposing by summarizing 388 information on FDA-approved drugs that could be applied immediately.

389

## **390 5. Conclusions**

This study highlights the potential of using deep learning algorithms to discover potential therapeutic targets for COVID-19. Although our results were consistent with those of several studies, our predictions were difficult to confirm without more knowledge of virus-host interactions. The GECN identified several genes that may be targets for COVID-19 treatment, including ABL1, ABL2, CSF2, IL-4, and IL-13. Clinical trials have shown promising results for Lenzilumab, a monoclonal antibody against GM-CSF. However, more studies are needed to confirm the effectiveness of

- 398 these drugs and their potential side effects. These findings provide a starting point for
- 399 further research into potential treatments for COVID-19.

400

## 402 Key Points

403	The graph-embedding convolution network (GECN), a novel deep learning
404	model, was developed to identify COVID-19-related genes and druggable
405	targets by analyzing COVID-19-related human protein interaction networks.
406	GECN identified several target genes, including ALB1/ALB2, CSF2, IL-4, and
407	IL-13, that are meaningfully correlated with COVID-19, potentially involved in
408	the entry of SARS-CoV-2 into host cells, cytokine storm, and pulmonary
409	fibrosis.
410	The GECN algorithm can predict COVID-19 drug targets rapidly, accurately,
411	and explainably, demonstrating its potential to expand our knowledge of disease
412	pathologies and accelerate drug discovery at a low cost.
413 414	Declarations
415	Ethics approval and consent to participate
416 417	All authors had ethical approval and consent to participate.
418	Consent for publication
419	All authors agreed with consent for publication.
420 421 422	Availability of data and materials
423 424	The data that support the findings of this study are available from the corresponding author and listing authurs upon reasonable request.
425 426	Conflict of Interest
427	Connet of interest
428	All authors declare that they have no conflicts of interest.
429	Funding
430	This work was supported by the Ministry of Science and Technology [Grant numbers
431	MOST 110-2314-B-A49A-504-MY3, MOST 110-2926-I-010-504, MOST 108-2923-
432	B-010-002-MY3, MOST 109-2823-8-010-003-CV, MOST 109-2622-B-010-006,
433	MOST 110-2321-B-A49A-502, and MOST 110-2923-B-A49A-501-MY3]; the
434	Development and Construction Plan of the School of Medicine, National Yang-Ming

435 University, now known as National Yang Ming Chiao Tung University [Grant number

436 107F-M01-0504]; Aiming for the Top University Plan, a grant from the Ministry of
437 Education [Grant number MOST 109-2823-8-010-003-CV].

## 438 Author contributions

439 Y-H.T. conceptualized the study and wrote the methodology, original draft, and 440 funding acquisition. H.H. wrote the original draft and reviewed and edited the 441 manuscript. C-N.Y. contributed to the investigation, validation, formal analysis, and 442 methodology. S-H.W. contributed to study investigation, validation, manuscript 443 writing, review, and editing, and arranged resources. O.K-S.L. supervised the study, 444 managed the project, and contributed to manuscript writing, review, and editing.

### 445 Acknowledgements

The authors acknowledge financial support from the Ministry of Science and Technology. The Development and Construction Plan of the School of Medicine, National Yang-Ming University, now known as National Yang Ming Chiao Tung University, and Aiming for the Top University Plan, a grant from the Ministry of Education. We thank Muen Biomedical and Optoelectronics Technologies Inc. and all our colleagues at National Yang Ming Chiao Tung University for their encouragement and support.

## 454 **References**

- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y *et al*:
   Epidemiological and clinical characteristics of 99 cases of 2019 novel
   coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020,
   395(10223):507-513.
- 459 2. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R: The COVID-19
  460 Cytokine Storm; What We Know So Far. Front Immunol 2020, 11:1446.
- 3. Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK: Drug
  repurposing approach to fight COVID-19. *Pharmacol Rep* 2020, 72(6):14791508.
- Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L,
   Walls AC, Park YJ *et al*: **De novo design of picomolar SARS-CoV-2 miniprotein inhibitors**. *Science* 2020, **370**(6515):426-431.
- 467 5. Dauparas J, Anishchenko I, Bennett N, Bai H, Ragotte RJ, Milles LF, Wicky BIM,
  468 Courbet A, de Haas RJ, Bethel N *et al*: Robust deep learning-based protein
  469 sequence design using ProteinMPNN. *Science* 2022, 378(6615):49-56.
- 470 6. Scarselli F, Gori M, Tsoi AC, Hagenbuchner M, Monfardini G: The graph neural
  471 network model. *IEEE transactions on neural networks* 2008, 20(1):61-80.
- 472 7. Zhang XM, Liang L, Liu L, Tang MJ: Graph Neural Networks and Their Current
  473 Applications in Bioinformatics. Front Genet 2021, 12:690049.
- 4748.Bruna J, Zaremba W, Szlam A, LeCun Y: Spectral networks and locally475connected networks on graphs. arXiv preprint arXiv:13126203 2013.
- 476 9. Kipf TN, Welling M: Semi-supervised classification with graph convolutional
  477 networks. arXiv preprint arXiv:160902907 2016.
- 478 10. Veličković P, Cucurull G, Casanova A, Romero A, Lio P, Bengio Y: Graph
  479 attention networks. arXiv preprint arXiv:171010903 2017.
- 480 11. Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M
  481 *et al*: Structural basis for inhibition of the RNA-dependent RNA polymerase
  482 from SARS-CoV-2 by remdesivir. *Science* 2020, 368(6498):1499-1504.
- 483 12. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann
  484 E, Chu HY, Luetkemeyer A, Kline S *et al*: Remdesivir for the Treatment of Covid485 19 Final Report. N Engl J Med 2020, 383(19):1813-1826.
- 486 13. Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Wang X, Yang H, Hong L, Wu N *et al*: An
  487 integrative drug repositioning framework discovered a potential therapeutic
  488 agent targeting COVID-19. Signal Transduct Target Ther 2021, 6(1):165.
- 489 14. Martin WR, Cheng F: Repurposing of FDA-Approved Toremifene to Treat
  490 COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. J
  491 Proteome Res 2020, 19(11):4670-4677.
- 492 15. Zeng X, Song X, Ma T, Pan X, Zhou Y, Hou Y, Zhang Z, Li K, Karypis G, Cheng F:
  493 Repurpose open data to discover therapeutics for COVID-19 using deep
  494 learning. Journal of proteome research 2020, 19(11):4624-4636.
- 495 16. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M,
  496 Savory E, Stebbing J: Baricitinib as potential treatment for 2019-nCoV acute
  497 respiratory disease. *Lancet* 2020, 395(10223):e30-e31.
- 498 17. Zhou Y, Hou Y, Shen J, Kallianpur A, Zein J, Culver DA, Farha S, Comhair S,
  499 Fiocchi C, Gack MU *et al*: A Network Medicine Approach to Investigation and
  500 Population-based Validation of Disease Manifestations and Drug

## 501 **Repurposing for COVID-19**. *ChemRxiv* 2020.

- Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
  Brightling C, Ustianowski A, Elmahi E *et al*: Dexamethasone in Hospitalized
  Patients with Covid-19. N Engl J Med 2021, 384(8):693-704.
- 50519.Fadaka AO, Sibuyi NRS, Madiehe AM, Meyer M: Computational insight of506dexamethasone against potential targets of SARS-CoV-2. J Biomol Struct Dyn5072022, 40(2):875-885.
- Sola 20. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD,
  Galli M, Ahn MY, Nahass RG *et al*: Remdesivir for 5 or 10 Days in Patients with
  Severe Covid-19. N Engl J Med 2020, 383(19):1827-1837.
- 511 21. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic
  512 M, Doncheva NT, Morris JH, Bork P *et al*: STRING v11: protein-protein
  513 association networks with increased coverage, supporting functional
  514 discovery in genome-wide experimental datasets. Nucleic Acids Res 2019,
  515 47(D1):D607-d613.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
  Dolinski K, Dwight SS, Eppig JT *et al*: Gene ontology: tool for the unification of
  biology. The Gene Ontology Consortium. *Nat Genet* 2000, 25(1):25-29.
- 519 23. Fabregat A, Sidiropoulos K, Viteri G, Marin-Garcia P, Ping P, Stein L, D'Eustachio
  520 P, Hermjakob H: Reactome diagram viewer: data structures and strategies to
  521 boost performance. *Bioinformatics* 2018, 34(7):1208-1214.
- Alanazi A, Nojiri C, Noguchi T, Kido T, Komatsu Y, Hirakuri K, Funakubo A, Sakai
  K, Fukui Y: Improved Blood Compatibility of DLC Coated Polymeric Material.
  ASAIO Journal 2000, 46(4):440-443.
- 52525.UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019,52647(D1):D506-d515.
- 527 26. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K,
  528 Cook J, Gillespie M, Haw R *et al*: The reactome pathway knowledgebase.
  529 Nucleic Acids Res 2020, 48(D1):D498-d503.
- 53027.Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-531Luria AH, Ware JS, Hill AJ, Cummings BB et al: Analysis of protein-coding532genetic variation in 60,706 humans. Nature 2016, 536(7616):285-291.
- 533 28. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, Mattingly
  534 CJ: Comparative Toxicogenomics Database (CTD): update 2021. Nucleic Acids
  535 Research 2020, 49(D1):D1138-D1143.
- Anno S, Hirakawa T, Sugita S, Yasumoto S: A graph convolutional network for
   predicting COVID-19 dynamics in 190 regions/countries. *Front Public Health* 2022, 10:911336.
- 53930.Kingma DP, Ba J: Adam: A method for stochastic optimization. arXiv preprint540arXiv:14126980 2014.
- 31. Wu Z, Pan S, Chen F, Long G, Zhang C, Philip SY: A comprehensive survey on
  graph neural networks. *IEEE transactions on neural networks and learning*systems 2020, 32(1):4-24.
- S44 32. Chiang W-L, Liu X, Si S, Li Y, Bengio S, Hsieh C-J: Cluster-gcn: An efficient
  algorithm for training deep and large graph convolutional networks. In: *Proceedings of the 25th ACM SIGKDD international conference on knowledge*discovery & data mining: 2019. 257-266.

- 54833.Inc. CCG: Molecular operating environment (MOE). In.: Chemical Computing549Group Inc. Montreal, QC, Canada; 2016.
- 55034.Aleman MM, Walton BL, Byrnes JR, Wolberg AS: Fibrinogen and red blood cells551in venous thrombosis. Thromb Res 2014, 133 Suppl 1(0 1):S38-40.
- 552 35. Clark AM, Labute P: **2D depiction of protein– ligand complexes**. *Journal of chemical information and modeling* 2007, **47**(5):1933-1944.
- 36. Sisk JM, Frieman MB, Machamer CE: Coronavirus S protein-induced fusion is
  blocked prior to hemifusion by Abl kinase inhibitors. *The Journal of general*virology 2018, 99(5):619.
- Solution 2014
   Solution
- 38. Dyall J, Coleman CM, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF,
  Olinger Jr GG, Jahrling PB, Laidlaw M, Johansen LM: Repurposing of clinically
  developed drugs for treatment of Middle East respiratory syndrome
  coronavirus infection. Antimicrobial agents and chemotherapy 2014,
  58(8):4885-4893.
- Sauvat A, Ciccosanti F, Colavita F, Di Rienzo M, Castilletti C, Capobianchi MR,
  Kepp O, Zitvogel L, Fimia GM, Piacentini M: On-target versus off-target effects
  of drugs inhibiting the replication of SARS-CoV-2. Cell Death & Disease 2020,
  11(8):656.
- 57040.Cagno V, Magliocco G, Tapparel C, Daali Y: The tyrosine kinase inhibitor571nilotinib inhibits SARS-CoV-2 in vitro. Basic & clinical pharmacology &572toxicology 2021, 128(4):621-624.
- 573 41. Zhao H, Mendenhall M, Deininger MW: Imatinib is not a potent anti-SARS574 CoV-2 drug. Leukemia 2020, 34(11):3085-3087.
- 57542.Thwaites R: Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory576profiles across the spectrum of disease reveal a distinct role for GM-CSF in577severe COVID-19 Sci Immunol 2021, 6(57):57.
- 578 43. Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM,
  579 Sturek JM, Ma JZ, Moreau GB, Donowitz JR: IL-13 is a driver of COVID-19
  580 severity. JCl insight 2021, 6(15).
- 58144.Shenoy S: SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons582learned one year into the pandemic: a systematic review. World Journal of583Critical Care Medicine 2021, 10(4):132.
- 584 45. Temesgen Z, Assi M, Shweta F, Vergidis P, Rizza SA, Bauer PR, Pickering BW,
  585 Razonable RR, Libertin CR, Burger CD: GM-CSF neutralization with lenzilumab
  586 in severe COVID-19 pneumonia: a case-cohort study. In: Mayo Clinic
  587 Proceedings: 2020. Elsevier: 2382-2394.
- 588









